4//SEC Filing
THERAGENICS CORP 4
Accession 0000795551-13-000021
CIK 0000795551operating
Filed
Oct 30, 8:00 PM ET
Accepted
Oct 31, 5:58 PM ET
Size
17.1 KB
Accession
0000795551-13-000021
Insider Transaction Report
Form 4
Zeman Janet
General Manager, CP Medical
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2013-10-29$1.44/sh−47,000$67,680→ 0 totalExercise: $1.44Exp: 2020-02-25→ Common Stock (47,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2013-10-29$1.71/sh−58,200$99,522→ 0 totalExercise: $1.71Exp: 2021-02-25→ Common Stock (58,200 underlying) - Disposition to Issuer
Common Stock
2013-10-29$2.20/sh−235,962$519,116→ 0 total - Disposition to Issuer
Common Stock
2013-10-26$2.20/sh−68,182$150,000→ 235,962 total - Disposition to Issuer
Stock Option (Right to Buy)
2013-10-29$0.93/sh−34,000$31,620→ 0 totalExercise: $0.93Exp: 2019-02-26→ Common Stock (34,000 underlying)
Footnotes (6)
- [F1]Contributed to Juniper Investment Partners, LLC prior to merger at a valuation of $2.20 per share.
- [F2]Shares of common stock which were disposed of in exchange for the right to receive $2.20 per share in cash pursuant to the Agreement and Plan of Merger, dated August 2, 2013 (as it may be amended, the "Merger Agreement"), by and between Juniper Acquisition Corporation (the "Purchaser") and Theragenics Corporation (the "Company") providing for the merger of Purchaser with and into the Company (the "Merger").
- [F3]2,200 shares of the total are owned indirectly through spouse and includes shares of common stock owned through the 401(k) Plan.
- [F4]The stock options, which provided for vesting in four equal annual installments beginning on 2-26-2010, were cancelled in exchange for the right to receive the difference between the exercise price of the option and $2.20 per share in cash pursuant to the Merger Agreement.
- [F5]The stock options, which provided for vesting in four equal annual installments beginning on 2-25-2011, were cancelled in exchange for the right to receive the difference between the exercise price of the option and $2.20 per share in cash pursuant to the Merger Agreement.
- [F6]The stock options, which provided for vesting in four equal annual installments beginning on 2-25-12, were cancelled in exchange for the right to receive the difference between the exercise price of the option and $2.20 per share in cash pursuant to the Merger Agreement.
Issuer
THERAGENICS CORP
CIK 0000795551
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000795551
Filing Metadata
- Form type
- 4
- Filed
- Oct 30, 8:00 PM ET
- Accepted
- Oct 31, 5:58 PM ET
- Size
- 17.1 KB